Hemostemix (CVE:HEM) Sets New 52-Week Low at $0.07

Shares of Hemostemix Inc. (CVE:HEMGet Free Report) reached a new 52-week low during trading on Monday . The company traded as low as C$0.07 and last traded at C$0.07, with a volume of 17000 shares changing hands. The stock had previously closed at C$0.07.

Hemostemix Stock Down 20.0 %

The company has a market capitalization of C$5.39 million, a PE ratio of -1.50 and a beta of 0.55. The business’s 50 day simple moving average is C$0.08 and its 200 day simple moving average is C$0.09.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.

Featured Articles

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.